LIXTE Biotechnology Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of Stock-based Compensation Costs

A summary of stock-based compensation costs for the three months ended March 31, 2020 and 2019 is as follows:

	Three Months Ended March 31,
	2020		2019

Related parties	$	—	$	12,936
Non-related parties		—		—
Total stock-based compensation costs	$	—	$	12,936

Summary of Stock Option Activity Including Options Form of Warrants

A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2020 is presented below.

			Weighted		Weighted Average Remaining
	Number of		Average		Contractual
	Shares		Exercise Price		Life (in Years)

Stock options outstanding at December 31, 2019		7,850,000	$	0.608
Granted		—		—
Exercised		—		—
Expired		—		—
Stock options outstanding at March 31, 2020		7,850,000	$	0.608		2.89

Stock options exercisable at March 31, 2020		7,850,000	$	0.608		2.89

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2020 are as follows:

Exercise Prices		Options Outstanding (Shares)		Options Exercisable (Shares)

$	0.120		450,000		450,000
$	0.150		300,000		300,000
$	0.160		200,000		200,000
$	0.200		500,000		500,000
$	0.280		400,000		400,000
$	0.500		4,200,000		4,200,000
$	1.000		1,000,000		1,000,000
$	1.100		300,000		300,000
$	2.000		500,000		500,000
			7,850,000		7,850,000